BioSpace News Archive

AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate

Regeneron Pharmaceuticals, Inc. announced the winners of the eighth annual Regeneron Prize for Creative Innovation, which celebrates and rewards cutting-edge thinking from the next generation of young scientists.

Bicycle Therapeutics plc announced that new translational data for BT5528 and preclinical data for tumor-targeted immune cell agonists will be presented during poster sessions at the American Association for Cancer Research Virtual Annual Meeting II on June 22-24, 2020.

Acceleron Pharma Inc. announced it will host a conference call and webcast on Wednesday, June 24, 2020 at 4:30 p.m. EDT to review the topline results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension.

ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s clinical candidate, EPI-7386, at the 2020 American Association for Cancer Research (“AACR”) Virtual Annual

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time

The company’s bi-specific antibody candidates significantly prolonged survival in models of metastatic human cervical and breast cancer

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it has entered into a $225 million loan agreement with funds managed by Oaktree Capital Management, L.P., a leading global investment firm.

Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the “Agreement”) entered on February 3, 2020 and modified on March 22, 2020.

MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation and publication of positive data from the company’s Phase 2a clinical trial of danicamtiv (formerly MYK-491) along with nonclinical data elucidating danicamtiv’s novel mechanism of action.